Analysts Set DaVita Inc. (NYSE:DVA) Target Price at $153.25

DaVita Inc. (NYSE:DVA) has received a consensus rating of “Reduce” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $151.75.

DVA has been the topic of several recent research reports. Barclays reduced their price target on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a research report on Thursday. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research report on Wednesday, October 8th. Bank of America reduced their price target on DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a research report on Wednesday, September 10th. Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Finally, Truist Financial set a $140.00 price target on DaVita in a research report on Tuesday, October 14th.

DaVita Stock Performance

Shares of NYSE:DVA opened at $118.73 on Tuesday. DaVita has a 1 year low of $117.73 and a 1 year high of $179.60. The stock has a market capitalization of $8.49 billion, a P/E ratio of 12.23, a PEG ratio of 0.91 and a beta of 1.13. The stock has a 50-day simple moving average of $131.21 and a 200-day simple moving average of $136.89.

DaVita (NYSE:DVA) last issued its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a return on equity of 815.62% and a net margin of 5.80%.The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.43 billion. During the same quarter in the previous year, the firm posted $2.59 EPS. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Analysts predict that DaVita will post 10.76 earnings per share for the current year.

Hedge Funds Weigh In On DaVita

A number of institutional investors have recently made changes to their positions in the business. iA Global Asset Management Inc. raised its position in shares of DaVita by 25.3% in the 3rd quarter. iA Global Asset Management Inc. now owns 10,440 shares of the company’s stock valued at $1,387,000 after purchasing an additional 2,110 shares in the last quarter. Covestor Ltd raised its position in shares of DaVita by 61.7% in the 3rd quarter. Covestor Ltd now owns 883 shares of the company’s stock valued at $117,000 after purchasing an additional 337 shares in the last quarter. Rakuten Investment Management Inc. acquired a new position in shares of DaVita in the 3rd quarter valued at approximately $19,875,000. Allstate Corp acquired a new stake in shares of DaVita during the 3rd quarter valued at approximately $250,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of DaVita by 4.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 4,499 shares of the company’s stock valued at $590,000 after acquiring an additional 197 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.